FOLLOW-UP-STUDY OF 24 FAMILIES WITH LI-FRAUMENI SYNDROME

被引:0
|
作者
GARBER, JE [1 ]
GOLDSTEIN, AM [1 ]
KANTOR, AF [1 ]
DREYFUS, MG [1 ]
FRAUMENI, JF [1 ]
LI, FP [1 ]
机构
[1] NCI,DIV CANC ETIOL,EPIDEMIOL & BIOSTAT PROGRAM,BETHESDA,MD 20892
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Li-Fraumeni cancer family syndrome is manifested by susceptibility to breast cancer, sarcomas, and other neoplasms in children and young adults. The present study utilized clinical follow-up data on 545 members of 24 Li-Fraumeni kindreds living and cancer-free at family ascertainment. Two hypotheses were tested based on a model of autosomal dominant genetic predisposition: (a) that syndrome cancers would continue to occur excessively during follow-up compared to the general population, and (b) that the tumors would occur primarily among those family members likely to carry the gene. Population cancer rates were compared with cancer rates in follow-up of the cohort from ascertainment to 1988. Risk of carrying the gene for the syndrome at the time of ascertainment was calculated for each family member under two models with somewhat different definitions of affection with the syndrome. Cancer occurrence after ascertainment was then analyzed according to the risks. Cancer did continue to occur excessively among the entire cohort during follow-up [relative risk (RR 2.1)]. The excess was greatest below age 20 (RR 21.1), declined with increasing age, and was most pronounced for neoplasms featured in the syndrome (RR 18.2). Among persons less than age 45, at least 87% of cancers occurred in those at higher risk of carrying the gene under both genetic models (RR 22.9 and 21.3). The clinical data, therefore, reliably identify individuals likely to carry a dominantly inherited gene conferring susceptibility to a specific constellation of neoplasms. Recent identification of a germ line mutation in the tumor suppressor gene p53 in persons with the syndrome may, if confirmed, have implications for ultimately defining the component tumors of the syndrome and for the causes and prevention of those tumors arising outside these families.
引用
收藏
页码:6094 / 6097
页数:4
相关论文
共 50 条
  • [1] Li-Fraumeni syndrome
    Concepcion Alonso-Cerezo, Maria
    Perez-Perez, Paola
    MEDICINA CLINICA, 2011, 137 (09): : 425 - 426
  • [2] 2 FAMILIES WITH THE LI-FRAUMENI CANCER FAMILY SYNDROME
    PEARSON, ADJ
    CRAFT, AW
    RATCLIFFE, JM
    BIRCH, JM
    MORRISJONES, P
    ROBERTS, DF
    JOURNAL OF MEDICAL GENETICS, 1982, 19 (05) : 362 - 365
  • [3] LI-FRAUMENI SYNDROME
    LI, FP
    AMERICAN JOURNAL OF HUMAN GENETICS, 1991, 49 (04) : 55 - 55
  • [4] The Li-Fraumeni syndrome
    Chompret, A
    BIOCHIMIE, 2002, 84 (01) : 75 - 82
  • [5] The Li-Fraumeni Syndrome
    Weiss, Johannes
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2018, 56 (10): : 1224 - 1225
  • [6] Li-Fraumeni syndrome
    Keymling, Myriam
    Schlemmer, Heinz-Peter
    Kratz, Christian
    Pfeil, Alexander
    Bickelhaupt, Sebastian
    Alsady, Tawfik Moher
    Renz, Diane Miriam
    RADIOLOGIE, 2022, 62 (12): : 1026 - 1032
  • [7] Multiple primary cancers in families with Li-Fraumeni syndrome
    Hisada, M
    Garber, JE
    Fung, CY
    Fraumeni, JF
    Li, FP
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (08): : 606 - 611
  • [8] Li-Fraumeni syndrome
    Limacher, JM
    EUROCANCER 96 - PROCEEDINGS OF THE NINTH CONGRESS, 1996, : 173 - 174
  • [9] The Li-Fraumeni syndrome
    Frebourg, T
    BULLETIN DU CANCER, 1997, 84 (07) : 735 - 740
  • [10] Li-Fraumeni syndrome
    Sejben Anita
    Tiszlavicz Laszlo
    Polyak Kornelia
    Kovacs Laszlo
    Maraz Aniko
    Torok Dora
    Lepran Adam
    Ottlakan Aurel
    Furak Jozsef
    ORVOSI HETILAP, 2019, 160 (06) : 228 - 234